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Introduction. In the genesis of Parkinson’s disease (PD) clinical phenomenology the exact nature of the association between
bradykinesia and affective variables is unclear. In the present study, we analyzed the gait characteristics and level of depression in
PD and healthy volunteers.Methods. Patients with PD (𝑛 = 48) and healthy controls (𝑛 = 52) were recruited for the present study.
Walking speed, stride length, and cadence were compared between groups while participants completed a goal-directed locomotion
task under visually controlled (VC) and visually noncontrolled conditions (VnC). Results. Significantly higher depression scores
were found in PD comparing to healthy control groups. In PD, depression was associated with gait components in the VC wherein
the place of the target was visible. In contrast, in healthy subjects the depression was associated with gait components in VnC
wherein the location and image of the target werememorized and recalled. In patients with PD and depression, the visually deprived
multitask augments the rate of cadence and diminishes stride length, while velocity remains relatively unchanged. The depression
associated with gait characteristics as a comorbid affective factor in PD, and that impairs the coherence of gait pattern. Conclusion.
The relationship between depression and gait parameters appears to indicate that PD not only is a neurological disease but also
incorporates affective disturbances that associate with the regulation of gait characteristics.
1. Introduction
Studies of gait characteristics in Parkinson’s disease (PD)
indicate that gait difficulties are commonly associated with
affective disturbances [1–3]. In patients with PD, voxel-based
morphometric and functional magnetic resonance imaging
(fMRI) studies report a correlation between depression and
gray matter impairment in the bilateral orbitofrontal cortex,
right temporal region, and limbic system [4]. The neural net-
works involved in gait and balance control include themesen-
cephalic motor region and the primary and secondary motor
cortex [5, 6]. In addition, the basal ganglia and supplementary
motor area (SMA), which play a role in the affective organi-
zation of goal-directed locomotion, have been implicated in
PD [7, 8]. The disruption of these regions induces deficits in
action execution and preparation.TheNPF’s 2012 Parkinson’s
Outcomes Project [9] found that depression has the greatest
impact on gait in patients with PD [7], but the association
between depression and gait characteristic can be found in
healthy elderly persons as well [10]. Previous studies have
demonstrated that the treatment of depression can signifi-
cantly alleviate motor symptoms. However, patients with PD
who receive gait training and other forms of exercise therapy
at an early stage demonstrate a significantly slower decline in
quality of life than those who received intervention later [9].
In PD, the essential components of gait pattern include
stride length, cadence, and velocity [11], wherein studies
report decreased stride length and velocity and increased
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Table 1: Demographic and clinical characteristics of Parkinson’s disease patients and healthy control persons. MEMS =Mini-Exam ofMental
Status;MADRS =Montgomery-A˚sbergDepression Rating Scale; VC= visually controlled condition; VnC= visually noncontrolled condition;
UPDRS = Unified Parkinson’s Disease Rating Scale; LEDD = levodopa equivalent daily dose.
Parkinson’s disease (𝑁 = 40) Healthy control (𝑁 = 49) 𝑡; 𝑍
𝑝 value
Gender, males/females 24/16 24/25 1.0 ns.
Age, mean ± SD, Min–Max 68.0 ± 8.1; 57–80 65.6 ± 5.6; 56–79 1.6 ns.
MEMS (in %) mean ± SD 91.0 ± 16.6 89.4 ± 10.5 0.6 ns.
MADRS total, mean ± SD 18.1 ± 9.1 11.6 ± 8.2 3.5∗∗∗
Cadence VC ( for 4m) 9.9 ± 3.5 8.0 ± 2.2 3.1∗∗
Cadence VnC (for 4m) 15.1 ± 6.9 9.8 ± 2.6 4.9∗∗∗
Step length VC (cm) 38.8 ± 11.1 45.9 ± 10.5 3.1∗∗
Step length VnC (cm) 28.1 ± 9.6 41.0 ± 10.8 5.9∗∗∗
Velocity VC (m/s) 0.6 ± 0.2 0.7 ± 2.3 1.2 ns.
Velocity VnC (m/s) 0.5 ± 0.2 0.6 ± 0.2 4.0∗∗∗
Disease duration, mean ± SD, Min–Max 6.7 ± 4.5; (1–16) N/D
UPDRS total mean ± SD, Min–Max 58.7 ± 25.5 (28–122) N/D
Mentation, mean ± SD 12.1 ± 6.2 N/D
Daily activities mean ± SD 11.7 ± 7.5 N/D
Motor examination mean ± SD 31.3 ± 13.7 N/D
Complication mean ± SD 4.0 ± 3.4 N/D
LEDD (mg) mean ± SD, Min–Max 712.2 ± 464.5 (154–1880) N/D
𝑝 < 0.01
∗∗; 𝑝 < 0.001∗∗∗.
cadence in patients with PD [12]. Many patients with PD
experience dysfunctional coordination during walking, and
falling is a frequent occurrence [13]. In particular, shorter
stride length without surface cues is often detected, and as
a compensatory mechanism, this plays an important role in
the development of gait hypokinesia [12, 14].
The aim of this study was to examine associations
between depression and gait characteristics in patients with
PD and healthy elderly control. The present study explores
between-group differences in gait pattern and investigates the
association between depression and the components of goal-
directed locomotion. The authors hypothesized that each
examined gait component, velocity, cadence, and stride
length, would significantly differ between patients with PD
and age-matched healthy controls. In addition, the rate of gait
disorderwould demonstrate a strong associationwith depres-
sion and quality of life in patients.
2. Method
2.1. Participants. Patients with PD (𝑛 = 48) and healthy age
and education in years fitted controls (𝑛 = 52) were recruited
for the present study. Patient demographics and clinical char-
acteristics are listed in Table 1. Healthy volunteer participants
were recruited from a pensioners’ club. Participants were
able to walk unsupported and they had normal or corrected
vision. All subjects had no history of psychiatric disease,
previous treatment with depression, or significant cognitive
impairment, were free of acute illness, and did not require
nursing care. Patients were recruited from the Outpatients
Clinics at the regional Department of Neurology UPMedical
School. Considering the required free walk locomotion test
condition, patients were only asked for participation who
were classified as patients with PD in Hoehn and Yahr
stages 3-4 and freezing was not detected [14, 15]. All patients
were prescribed levodopa (L-dopa). Cognitive impairment
was evaluated using the Mini Mental State Examination
(MMSE) [16, 17]. Nondemented persons were only invited
to participate in the experimental part of study. In addition,
the Montgomery-A˚sberg Depression Rating Scale (MADRS)
was used to examine affective disturbances [18]. In addition,
all subjects were right-handed, as assessed by the Edinburgh
Handedness Inventory [19]. Handedness Laterality Quotients
were 70% or higher for the right hand in all subjects.
The Unified Parkinson’s Disease Rating Scale (UPDRS)
[20] was applied to evaluate the PD symptoms (Table 1) and
the total UPDRS scores have been used in the statistical
analysis. Patients and healthy controls were excluded if
they received an MMSE score of less than 23. Following
MMSE examination, 40 patients with PD and 49 controls
were recruited for experimental analysis. All participants
provided written informed consent prior to experimentation.
This study was performed in accordance with the Helsinki
Declaration and approved by the Regional Research Ethics
Committee of the Medical Center in the State University.
2.2. Procedure. Global motor function was assessed using
the UPDRS by a movement disorder specialist (N.K), when
medication was controlled during regular visits to the out-
patient clinic. Patients’ L-dopa equivalent dosage (LED) was
calculated as described by Tomlinson et al. [21]. All patients
took theirmedication in themorning approximately 2 h prior
Parkinson’s Disease 3
Table 2: Pearson’s correlation of gait characteristics and affective scales in the healthy control group in two conditions (VC = visually
controlled condition; VnC = visually noncontrolled condition), MADRS (Montgomery-A˚sberg Depression Rating Scale).
(1) (2) (3) (4) (5) (6) (7)
(1) Velocity VC −.84∗∗∗ .87∗∗∗ .80∗∗∗ −.61∗∗∗ .71∗∗∗ −.21
(2) Cadence VC −.94∗∗∗ −.64∗∗∗ .79∗∗∗ −.66∗∗∗ .27
(3) Stride length VC .72∗∗∗ −.78∗∗∗ .75∗∗∗ −.21
(4) Velocity VnC −.73∗∗∗ .78∗∗∗ −.32∗
(5) Cadence VnC −.86∗∗∗ .39∗∗
(6) Stride length VnC −.31∗∗
(7) MADRS
𝑝 < 0.05
∗; 𝑝 < 0.01∗∗; 𝑝 < 0.001∗∗∗.
to examination. Participants were invited into a laboratory
room and asked to perform two subsequent tasks that were
originated from the clinical practice and modelled the every-
day locomotion. To assess the gait characteristics, the patients
and healthy controls were directed to approach a target in
an examination room, where the main gait components of
PD were evaluated using operationalized methods. At the
beginning of the trial, participants were instructed to stand
in front of a visible gray cross target (25 × 25 cm) placed 4m
away on awhite wall.Theywere directed to lift their right arm
and to point to a target with their right index finger. Next,
while maintaining this arm and finger position, participants
were instructed to approach the target and touch it. The
goal-directed locomotion test contained two types ofmultiple
task conditions: a simple visual control (VC) and complex
nonvisual control (VnC). The first trial was conducted with
VC and served as an introductorymotor exercise to assess the
gait characteristics of participants and to determine stability
in circumstances with VC. Following the introductory VC
task, three test trials were performed in the VnC condition.
During this task, at the start line, after a visual fixation of the
target, the participant’s eyes were covered by nontransparent
swimming glasses and asked to approach and touched the
estimated place of the target. The participants were followed
up by an assistant. The procedure was safe or falling or other
complications did not happen. Under VC and VnC condi-
tions, the participants’ gait characteristics, including cadence,
stride length, and velocity, were recorded and assessed on a
large carpet using a visible scaled ruler. The measurement of
gait components was initiated when patients took their first
step toward the target andmaintained throughout their route
towards the goal. Offline video recordings of the route of
locomotion were analyzed by two independent raters. Three
main gait parameters were assessed, including velocity (m/s),
cadence (number of steps from start to target), and stride
length (distance in cm between successive heel contact points
of the same foot).
2.3. Statistical Analysis. SPSS version 22.0 was used for
statistical analysis (Chicago, IL, US). For group comparisons,
patients with PD and healthy participants were compared. A
two-tailed 𝑡-test for parametric and a Mann–Whitney 𝑈 test
for nonparametric data were used to assess between-group
differences in age, sex, education level, MADRS, cadence,
stride length, and velocity. Kolmogorov-Smirnov tests were
used to assess the normality of variables. Logarithmic
transformation was applied for cadence data in parametric
comparisons. Moreover, Pearson’s correlation analyses were
used in the control group to assess within-group associa-
tions between movement parameters and MADRS data. In
addition, in the patients’ group, Pearson’s correlation analyses
were performed to evaluate the relationship between L-dopa
dosage andMADRS, disease duration, cadence, stride length,
and velocity variables. Gait data differences between groups
were analyzed using multivariate test initially (MANCOVA,
adjusted for age and gender), with follow-up univariate tests
(ANOVA). For multiple comparisons between gait data and
depression (following Feldmann et al.’s [4] method MADRS,
cutoff = 13 was used) a 2 × 2 × 2 Analysis of Variance
(ANOVA) was used with regard to the factors of velocity,
cadence, stride length, and MADRS for all dependent vari-
ables (two conditions: locomotion with VC and locomotion
with VnC) in healthy controls and patients with PD. Post
hoc Scheffe´-tests were applied to evaluate significant pairwise
differences between variables. Reasonable results were listed
in post hoc tables only. Levene’s test was used to detect
differences in the homogeneity of variance. Analyses were
two-tailed and significance was set at 0.05.
3. Results
3.1. The Coherence of Gait Pattern and the Related Affective
Associations in Visually Controlled and Visually Noncon-
trolled Conditions. Correlation analyses in the control group
revealed a coherent pattern for velocity, stride length, and
cadence. Under both VC and VnC conditions, the associ-
ation of the three main gait components demonstrated the
same coherent configuration (Table 2). During goal-directed
locomotion, fast walkers typically exhibit a small cadence and
long stride length while small cadence associated with long
stride length. In the present task, the depression did not show
a significant association with gait pattern under a simple VC
conditions; however, in the multitask VnC condition, high
depression scores correlated with low velocity, high cadence,
and short stride length.
The correlation analysis of patients with PD demon-
strated a coherent gait pattern (low velocity, high cadence,
and long stride length) similar to that of healthy controls
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Table 3: Persons’ correlation of gait characteristics and depression scale in Parkinson’s disease group in two conditions (VC = visually
controlled condition; VnC = visually noncontrolled condition): MADRS (Montgomery-A˚sberg Depression Rating Scale); UPDRS (Unified
Parkinson’s Disease Rating Scale); LED values; duration of disease.
(1) (2) (3) (4) (5) (6) (7) (8) (9) (10)
(1) Velocity VC −.86∗∗∗ .92∗∗∗ .75∗∗∗ −.74∗∗ .21 −.34∗ −.44∗∗ .34∗∗ .21
(2) Cadence VC −.91∗∗∗ −.73∗∗ .82∗∗∗ −.20 .33∗ .37∗∗ −.27 −.24
(3) Stride length VC −.75∗∗∗ −.79∗∗∗ .16 −.31∗ −.36∗ .34∗ .22
(4) Velocity VnC −.85∗∗∗ .42∗∗ −.25 −.34∗ .18 .16
(5) Cadence VnC −.34∗ .25 .38∗∗ −.14 −.16
(6) Stride length VnC −.13 −.15 .04 .08
(7) MADRS .47∗∗ −.28 −.21
(8) UPDRS −.03 .09
(9) LED values .63∗∗∗
(10) Duration
𝑝 < 0.05
∗; 𝑝 < 0.01∗∗; 𝑝 < 0.001∗∗∗.
in both the VC and VnC conditions. However, contrary to
healthy controls, the depression was linked to low velocity,
high cadence, and short stride length in the VC condition.
A similar association was not found in the multitask VnC
condition between depression and gait parameters. This
indicates that the depression associated gait pattern was
reverted in the VC and VnC conditions for the control
and PD groups. PD-specific UPDRS scores correlated with
depression and all gait parameters excluding stride length in
the VnC condition. LED values correlated with velocity and
stride length only in the VC condition, and disease duration
was found to associate with L-dopa dose (Table 3).
3.2. Multivariate Analyses and Multiple Comparisons. Com-
parison of the gait variables in the two groups (PD and
healthy controls) showed the presence of significant differ-
ences concerning the mean gait scores [MANCOVA Wilks
𝜆 = .569; 𝐹(6, 88) = 10.083; 𝑝 < 0.001], after controlling
for age and gender. Analysis of covariance found significantly
lower stride length and higher cadence in patients with PD
compared with healthy controls in VC and VnC conditions.
The velocity was significantly different in the two groups in
the VnC condition only.
3.3. Pairwise Results by Scheffe´-Test in Cadence. Comparisons
of cadence between healthy controls and patients with PD
indicated significant differences, wherein patients with PD
demonstrated a significant increase in cadence (Table 4).
Similar significant results were identified in comparisons of
condition (VC × VnC) and with regard to affective distur-
bance (depression × nondepression). Higher cadence was
identified in patients with PD, in the VnC condition, and in
participants with a higher depression score. Healthy controls
× the VnC condition demonstrated lower cadence compared
to patients in the VnC condition. In addition, comparison
of healthy controls with depression versus PD patients with
depression revealed an increased cadence in PD patients who
suffered from depression. Therefore, higher levels of depres-
sion and visuospatially deprived examination conditions
(VnC) augmented the contrast in cadence between healthy
controls and patients with PD, wherein cadence is increased
in PD. Further analysis indicated that cadence was increased
in the VC condition in patients with PD and depression,
compared to the VnC condition. Therefore, patients with
PD and higher depression scores demonstrated increased
cadence in visuospatially deprived conditions.
3.4. Pairwise Results by Scheffe´’s Test in Stride Length. Differ-
ences in stride length between the VC and VnC conditions
were significant, wherein stride length was reduced in the
visually deprived condition. Patients demonstrated a signif-
icantly shorter stride length than healthy controls (Table 4).
Participants with elevated depression scores exhibited shorter
stride length than participants without indications of depres-
sion. In addition, significant differences were identified
between nondepressed healthy subjects and nondepressed
patients with regard to stride length, wherein the stride length
of patients with PD was reduced. Next, stride length was
found to decrease in the VnC condition in patients with PD,
compared to the VC condition. Therefore, it is possible to
suggest that, in patients with PD and depression, the VnC
condition significantly decreases stride length.
3.5. Pairwise Results by Scheffe´’s-Test in Velocity. Higher
velocitywas detected in healthy controls compared to patients
with PD. Moreover, lower velocity was identified in PD
patients in the VnC condition compared to healthy partici-
pants (Table 4).
4. Discussion
The main result of this study is that when PD and control
participants were tested during goal-directed locomotion
high cadencewas associatedwith reduced stride length, while
slow walking velocity was associated with high cadence and
short stride length in both groups but different in activity rate.
When analyzing level of depression in controls, depression
did not associate with velocity and other gait components in
the common VC condition; however, high levels of depres-
sion showed an association with low velocity, high cadence,
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Table 4: Multiple group comparison between patient x control, visually x nonvisually controlled conditions, and depression x nondepression
groups with several gait parameters. He = healthy control condition, PD = Patient’s condition, VC = visually controlled condition, VnC =
visually noncontrolled condition, NoD = nondepressive condition, and DE = depressive condition.
Gait
parameters
Mean (SD) ANOVA
intercept
Group
comparisons
Scheffe´ post
hoc 𝑝He PD VC VnC NoD DE
Cadence 8.9 (2.5) 12.5 (6.0) 8.86 (3.0) 12.7 (5.6) 9.07 (2.8) 11.08 (5.7)
𝐹 = 904.14
df = 1;
𝑝 < 0.001
He versus PD <0.001
VC versus VnC <0.001
NoD versus DE <0.001
He × VnC versus
PD × VnC <0.001
He × DE versus PD
× DE <0.004
PD × VC × DE
versus PD × VnC ×
DE
<0.006
Stride length
(cm) 43,5 (10.8) 33.4 (11.6) 42,8 (11,2) 35,2 (12,1) 42.7 (11.3) 35.6 (12.1)
F = 1813
df = 1;
𝑝 < 0.001
He versus PD <0.001
VC versus VnC <0.001
NoD versus DE <0.001
He × NoD versus
PD × NoD <0.005
PD × VC × DE
versus PD × VnC ×
DE
<0.047
Velocity (m/s) 0.65 (1.44) 0.54 (0.39) 0.65 (0.45) 0.53 (0.74) 0.59 (1.61) 0.40 (0.42)
F = 185,48
df = 1;
𝑝 < 0.001
He versus PD <0.001
He × VnC versus
PD × VnC <0.048
and short stride length in the multitask VnC condition. In
patients, the association of depression and gait components
demonstrated a reverted pattern compared to controls. The
depression was associated with velocity, stride length, and
cadence in VC but not in VnC.
In addition, UPDRS scores were associated with all gait
parameters excluding stride length in the VnC condition.
The UPDRS, L-dopa equivalent doses, and illness duration
showed the conventional syndrome specific associations but
need to note that higher L-dopa equivalent doses associated
with higher velocity and longer stride length but not with
cadence and depression in patients with PD. With regard to
intercorrelation analysis of the clinical components of gait,
the gait pattern coherence remained intact while participants
approached a target in both the VC and VnC conditions. The
present results are consistent with the findings of previous
studies, indicating that gait patterns are relatively coherent in
the early stages of PD compared to healthy participants (low
velocity, high cadence, and short stride length). However, in
PD, velocity was reduced, cadence was increased, and stride
length was shorter than in healthy controls [12]. The reduc-
tion in velocity relates to PD-specific visuospatial and pro-
prioceptive impairments [11, 14], in the present case that was
significant in complex multiple task in goal-directed loco-
motion without visual control condition. This indicates that,
in patients with PD, depression linked to everyday activities,
wherein walking (in a simple VC environment) is a difficult
task for the majority of patients. Nevertheless, in the VnC
(complex environment without visual guidance) condition,
depression does not significantly associate with the goal-
directed locomotion of patients with PD. To evaluate this data
we need to note that depression-related gait pattern is linked
to PD-specific visuospatial ability [22], which is associated
with the hemispatial onset of PD symptoms [23], the applied
L-dopa equivalent dose [24], disease duration, and current
off/on effects [25]. In this study the off/on state had been
controlled by the timing of examination, but the hemispatial
onset of PD symptoms had not been the object of the present
investigation.
It is necessary to establish that, in complex environmental
conditions, when participants completed a VnC multitask,
gait pattern remained relatively congruent, but patients with
PDdemonstrated a slower velocity, reduced stride length, and
higher cadence compared to healthy controls. The reduction
in velocity was significant in the visually deprived condition
and in patients with elevated depression. Depression was
associated with low velocity, reduced stride length, and
elevated cadence in healthy controls inVnC conditions.How-
ever, in patients this effectwas identified in theVC rather than
the VnC condition.
The main results of this study arose from multiple com-
parisons of gait parameters and affective values between VC
and VnC conditions in patients with PD and healthy con-
trols. This analysis indicated that the visuospatially deprived
multitask augments the rate of cadence and diminishes stride
length in patients with PD and depression, while velocity
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remains unchanged. These results support previous findings
that stride length and cadence are regulated by a bottom-
up related reciprocal compensation mechanism [9, 12, 13,
26]. Our results indicate that this compensatory mechanism
interacts with depression; however, the depression-related
sensitivity of gait components differs. Multivariate analyses
demonstrated that depression, first of all in visually noncon-
trolled multitask condition, produced a general reduction in
stride length and increment in cadence in patients with PD
to compare healthy controls. Velocity, first of all in visually
noncontrolledmultitask condition, was lower in patientswith
PD; however, the influence of depression on this condition
has not been detected. It can be supposed that, in these
patients, the reduction in the velocity of goal-directed loco-
motion was likely compensated by higher cadence and
shorter stride length.
Lemke et al. [26] reported that depression, Parkinsonian
posture, and gait demonstrate a number of similarities. The
present evaluation of the relationship between depression and
gait parameters appears to indicate that PD not only is a
neurological disease but also incorporates a state of affective
disturbance that influences the regulation of gait characteris-
tics. In early stage of PD patients, first of all visually deprived
multitask situation, depression specially modifies cadence
and stride length but has no significant inhibition effect on
the velocity of the gait. Consequently, the coherence of the
gait pattern gets weaker. The correlation analyses indicated
that in common visually controlled condition the depression
and gate components showed a correlation pattern in PD (low
velocity and stride length and high cadence); however, when
multitask was applied in the visually noncontrolled condition
the association between depression and gait features disap-
peared. Limitations to our study include consideration of
depression as an aggregated score and its affective character-
istic, apathy, quality of life, and the type of cognitive decline
had not been detailed. Since the visuospatial disorder and the
laterality of the firstmotor symptomsonset in PDare essential
component in the gait control on these domains further
research is needed.
5. Conclusion
The depression links to gait characteristics as a comorbid
affective factor in PD. The findings reported above serve
as a laboratory-based demonstration of gait specificity in
PD and revealed depression-related dissimilarities in healthy
and Parkinsonian gait patterns. Considering the associations
between gait and depression these data might aid the devel-
opment of exact clinical diagnoses, to conduct more efficient
rehabilitation training for gait disturbances.
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